A Facile Approach to Functionalize Cell Membrane-Coated Nanoparticles

Hao Zhou¹, Zhiyuan Fan¹, Pelin K. Lemons¹ & Hao Cheng^{1,2,*}

Supplementary data



Figure S1. Characterization of NPs. A) Zeta-averaged sizes of PLGA-NPs and DiD-labeled PLGA-NPs prepared using PLGA acetone solutions at various concentrations. (5, 7.5, 10, 12, 15 mg/mL) Values are mean \pm s.d., n=3. B) Zeta-averaged sizes of PLGA-NPs, RBCM-NPs and PH20-RBCM-NPs. Vesicles are membrane-formed particles without PLGA-NP core. Values are mean \pm s.d., n=3. C) Zeta potential of PLGA-NPs, RBCM-NPs and PH20-RBCM-NPs. Values are mean \pm s.d., n=3.



Figure S2. rHuPH20 activity assay demonstrating the covalent conjugation of rHuPH20 on the RBC membranes. (A) Standard curve of free rHuPH20 activity ranging from 0.1 U/mL to 1000 U/mL. Values are mean \pm s.d., n=3. (B) rHuPH20 activity of RBCs or RBC membrane vesicles that are modified or prepared under conditions with or without linker and/or rHuPH20 thiolation. Free rHuPH20 served as a positive control. Vesicles refer to RBC membrane-formed particles without PLGA-NP core. The RBC membranes were isolated to form small vesicles (RBCM vesicles) in order to increase the access of conjugated rHuPH20 to HA matrix in the assay. Values are mean \pm s.d., n=3.

# of Effective rHuPH20 per NP	Short linker	Long linker
Small NP	8.10 ± 1.43	8.34 ± 0.98
Large NP	11.5 ± 2.33	14.4 ± 2.12



Figure S3. Number of effective rHuPH20/NP. Values indicate mean \pm s.d. (n=3).



Exclusion area per cell

Before rHuPH20	After rHuPH20	Depleted
treatment	treatment	Matrix area
128.3 ± 21.9 µm²	$40.2 \pm 6.4 \ \mu m^2$	88.1 µm²

Figure S4. Measurement of the pericellular HA matrix around PC3 cells via a RBC exclusion assay (scale bar = $20 \ \mu m$). PC3 cells were treated without and with 1000 U/mL of free rHuPH20 for 2 hours before adding fixed-RBCs. The arrow is pointing to the matrix. The images were analyzed through ImageJ, and the matrix area/cell was calculated. Values are mean \pm s.d. (n=10).



Figure S5. Effect of cell membrane/PLGA-NP surface area ratio on RBCM-NP blood circulation. For every mg of PLGA-NPs, a series amount of RBC membranes from 350, 200, 150 μ L of blood were mixed and extruded together. The resulting RBCM-NPs were administered through tail vein injection at 100 μ L of 8 mg/mL per mouse. At different time points, blood was collected and the fluorescence intensity in plasma was detected via TECAN at 600nm/655nm. Values indicate mean \pm s.d. (n = 3-4).



Figure S6. Relative rHuPH20 activity on modified RBCs before and after quenching unreacted thiol and maleimide groups with PEG_{2K} -maleimide and PEG_{2K} -thiol sequentially. Value indicates mean \pm s.d. (n = 3).